Innovative Technology Enhances Cellular and Molecular Insights into Kidney Lesions

Researchers have demonstrated the feasibility of a morphological-based approach to interpreting spatial transcriptomic (ST) data, helping to improve understanding of the lesions that occur in chronic kidney disease (CKD), at both the cellular and molecular levels. A recent study 打開新的分頁／視窗 in The American Journal of Pathology 打開新的分頁／視窗, published by Elsevier, details how this new method could lead to the identification of new biomarkers and therapeutic strategies for patients.

ST technologies are a rapidly developing new tool for measuring RNA in their original spatial context, giving a molecular mechanistic dimension to tissue morphology. The application of ST technologies has already yielded important insights across many different tissues and disease models. By combining profiling of gene expression patterns with the spatial information of cells in tissues, ST provides a more complete understanding of the molecular and cellular organization of tissues and lesions.

Lead investigator Benjamin D. Humphreys, MD, PhD, Division of Nephrology, Department of Medicine, and the Department of Developmental Biology, Washington University in St. Louis, explains, "During ST data analysis, computationally-annotated clusters are often superimposed on a histological image. However, tissue morphology by standard light microscopic pathologic evaluation is not considered. This may preclude assimilation of important information that can help interpret the ST data. The kidney is a particularly heterogeneous organ in morphologic terms, with a high degree of spatial and temporal lesion variability often present in pathologic situations. We conducted a histopathological-based analysis of spatial transcriptomics on four human kidney samples with CKD, corresponding as closely as possible to how a kidney biopsy is interpreted in clinical practice."

The study demonstrates how:

• Morphological and ST cross-analysis can help identify lesions within tissues such as tertiary lymphoid organs in the kidney.

• The cellular composition of a specific lesion can be determined, sometimes beyond its morphological appearance, as in the case of the papillary tumor identified.

• The molecular mechanisms of lesion processes can be identified by comparing lesions at different stages, as in the case of glomerular fibrosis or tubular atrophy.

• To identify potential new genes such as CXCL12 or FXYD5 that may be involved in glomerular fibrosis.

• This method combining traditional histopathology with ST data can pave the way for the future of molecular microscopy and precision pathology.

Lead author Pierre Isnard, MD, PhD, Division of Nephrology, Department of Medicine, and the Department of Developmental Biology, Washington University in St. Louis, concludes, "ST technologies are new and increasingly used in the life sciences, but there is a lack of studies showing their benefits and applications. Here, we demonstrate the complementary nature of these technologies to standard morphological analysis of tissue for identifying, classifying, and understanding lesions. The value of these technologies in healthcare remains to be demonstrated. However, these methods provide a better understanding of the cellular and molecular mechanisms of diseases, which may help identify new biomarkers and/or therapeutic strategies for patients. "

Notes for editors

The article is “Histopathologic Analysis of Human Kidney Spatial Transcriptomics Data: Toward Precision Pathology,” by Pierre Isnard, Dian Li, Qiao Xuanyuan, Haojia Wu, and Benjamin D, Humphreys (https://doi.org/10.1016/j.ajpath.2024.06.011 打開新的分頁／視窗). It appears in The American Journal of Pathology, volume 195, issue 1 (January 2025), published by Elsevier.

The article is openly available at https://ajp.amjpathol.org/article/S0002-9440(24)00274-8/fulltext 打開新的分頁／視窗.

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 406 1313 or [email protected] 打開新的分頁／視窗 to request a PDF of the article or more information. To reach the study’s authors contact Benjamin D. Humphreys, MD, PhD, at [email protected] 打開新的分頁／視窗, or Pierre Isnard, MD, PhD, at [email protected] 打開新的分頁／視窗.

The study was supported by NIH grants UC2DK126024 and U54DK137332, Assistance Publiquee–Hôpitaux de Paris (France), Philippe Foundation (United States), and Institut Servier Foundation (France).

About The American Journal of Pathology

The American Journal of Pathology 打開新的分頁／視窗, official journal of the American Society for Investigative Pathology 打開新的分頁／視窗, published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. https://ajp.amjpathol.org 打開新的分頁／視窗

關於 Elsevier

身為科學資訊與分析的全球領導者，Elsevier 協助研究人員與醫療照護專業人員推動科學發展，改善醫療成果，造福社會。我們以可信賴、以實證為基礎的內容和先進的 AI 數位技術為基礎，透過創新的解決方案促進洞察力和關鍵決策。

140 多年來，我們一直為研究和醫療保健界的工作提供支援。我們全球 9,500 名員工，包括 2,500 名技術人員，致力於支援研究人員、圖書館館長、學術領袖、資金提供者、政府、研發密集型公司、醫生、護士、未來醫療保健專業人員和教育工作者的重要工作。我們的 2,900 種科學期刊和經典參考工具書包括其領域中最重要的書籍，包括 Cell Press、The Lancet 和 Gray's Anatomy。 我們與愛思唯爾基金會 (Elsevier Foundation 打開新的分頁／視窗) 合作，與我們服務的社群攜手合作，在發展中國家和世界各地的科學、研究和醫療保健領域推動包容性和多樣性。 Elsevier 是 RELX 打開新的分頁／視窗 的一部分，RELX 打開新的分頁／視窗 是一家為專業和商業客戶提供以資訊為基礎的分析和決策工具的全球供應商。有關我們的工作、數位解決方案和內容的更多資訊，請造訪 www.elsevier.com 。